|
Summary
of clinical outcomes and immune responses.
|
Patient
|
Disease
Sitesa
|
Clinical
Responseb
|
Immune
Responsec
(Melan-A)
|
Immune
Responsec
(Flu)
|
Survival
(days)
|
|
1
|
skin,
lung
|
CR
|
Od
|
Oe,
D
|
750+
|
|
2
|
lung,
s.c.
|
PD
|
|
|
490
|
|
3
|
liver, lung, paraspinal, pelvis
|
PD
|
|
|
162
|
|
4
|
lung, liver, LN, local
|
NE/PD
|
|
|
17
|
|
5
|
s.c., liver
|
SD
|
|
|
411
|
|
6
|
in-transit
|
MR
|
|
C
|
750+
|
|
7
|
liver
|
PD
|
|
C
|
300
|
|
8
|
lung, LN
|
PD
|
|
|
335
|
|
9
|
lung, liver, skin, spleen
|
PD
|
|
D
|
342
|
|
10
|
lung, liver
|
PD
|
C
|
|
539
|
|
11
|
liver, bone, lung
|
NE/PD
|
|
|
26
|
|
12
|
liver
|
NE
|
|
|
605
|
|
13
|
LN, lung, liver
|
SD
|
|
D
|
266
|
|
14
|
LN, bone, liver
|
PR
|
|
C, D
|
750+
|
|
15
|
s.c., lung, liver
|
MR
|
D
|
C
|
750+
|
|
16
|
lung, LN
|
MR
|
|
C
|
415
|
|
17
|
LN, skin
|
PD
|
|
|
750+
|
|
18
|
LN
|
SD
|
C
|
|
465
|
|
19
|
lung, liver
|
PD
|
|
|
416+
|
|
20
|
lung, liver, LN
|
SD
|
|
|
117
|
|
21
|
soft tissue, LN, pleura
|
SD
|
|
D
|
241
|
|
22
|
LN
|
SD
|
|
C
|
439
|
|
23
|
lung, spleen, adrenal
|
PD
|
|
C
|
285
|
|
24
|
LN, lung, spleen
|
PD
|
C
|
C
|
638
|
|
25
|
lung, bone, pleura
|
PD
|
|
|
81
|
|
26
|
LN
|
PD
|
|
|
750+
|
|
27
|
skin, LN
|
PD
|
D
|
|
60+
|
|
28
|
s.c., skin, LN, lung
|
PD
|
|
|
60
|
aDisease sites: LN, lymph node.
bClinical outcome: CR, complete response; PR, partial
response; MR, mixed response; PD, progressive disease; SD, stable
disease; NE, not evaluable.
cImmune responses: D, DTH; C, CTL; O, other.
dNegative in split-well assay; positive ELIspot assay.
eNegative in split-well assay; positive response in
bulk culture cytotoxicity assay.
|
